Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × DNA Repair-Deficiency Disorders × omega-N-Methylarginine × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Head & Neck 1 Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 2 Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Melanoma 1 DNA Repair-Deficiency Disorders 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 1 omega-N-Methylarginine 1 Restraint, Physical 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03236935 2025-03-10

Phase Ib of L-NMMA and Pembrolizumab

The Methodist Hospital Research Institute

Phase 1 Active not recruiting

DermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, DNA Repair-Deficiency Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡